November 8, 2023 News by Marisa Wexler, MS High blood NfL levels predict greater MS disability in year or two: Study Elevated blood levels of neurofilament light chain (NfL), an established biomarker of nerve damage, are associated with a higher risk of near-term disability worsening in people with multiple sclerosis (MS), according to a large study. Findings imply that there’s usually a window of time ā about a year or…
October 17, 2023 News by Marisa Wexler, MS ECTRIMS 2023: Blood biomarker may help to predict disability in MS Blood levels of neurofilament light chain (NfL), a marker of nerve damage, were seen to increase about a year or two prior to disability worsening in people with multiple sclerosis (MS), particularly among patients whose disease progressed without any relapse activity. That’s according to new data presented at the…
October 2, 2023 News by Marisa Wexler, MS Most disability worsening on Ocrevus not tied to relapses: Study Among multiple sclerosis (MS) patients treated with Ocrevus (ocrelizumab), most of the disability worsening they experience is not associated with any relapse activity, according to an analysis of real-world data. “We present real-world data from our multiple sclerosis center underlining that in a typical population of relapsing MS…
September 28, 2023 News by Marisa Wexler, MS Lemtrada controlled RRMS disease activity more than a decade Over more than a decade of treatment with Lemtrada (alemtuzumab), relapse rates were low and about half of people with relapsing-remitting multiple sclerosis (RRMS) remained free of confirmed disability worsening, according to final results from the open-label TOPAZ clinical trial. “To our knowledge, this report represents the longest…
July 31, 2023 News by Marisa Wexler, MS Relapses found to drive disability worsening in 1st years of MS In people with relapsing forms of multiple sclerosis (MS), relapses that occur in the first few years after the disease develops have a strong impact on rates of disability worsening ā but after about 2.5 years, more relapses don’t consistently result in a greater worsening of disability, according to…
May 24, 2023 News by Patricia Valerio, PhD Self-reported physical health may predict RRMS disability worsening People withĀ relapsing-remitting multiple sclerosis (RRMS) who report better physical health are significantly more likely to see disability progression after three years, an observational study found. The findings suggest this patient-reported outcome measure may help predict long-term disability worsening in people with the condition. āOur findings…
April 5, 2023 News by Andrea Lobo, PhD Quitting smoking or moving to snuff may help slow MS progression Smoking and exposure to secondhand smoke are both associated with significantly faster disease progression in people with multiple sclerosis (MS), but snuff, a smokeless tobacco product placed behind the upper lip, seems to slow MS progression, a study in Sweden suggests. Findings also linked smoking and secondhand exposure, also…
September 23, 2022 Columns by Ed Tobias My Wife Says I Should Follow My Own (MS) Advice I have to be honest: I havenāt always been honest. I donāt always practice what I preach. My wife called me out on that as we watched an interview I did recently about multiple sclerosis on Montel Williams’ podcast. āYou should follow your own advice,ā she told me.
March 1, 2022 News by Marisa Wexler, MS #ACTRIMS2022 ā Spinal Cord Atrophy Predicts ‘Silent Progression’ in Early MS A faster rate of atrophy in the spinal cord of people in earlier stages ofĀ multiple sclerosis (MS) is likely to indicate “silent progression” ā worsening disability in the absence of relapses ā and a swifter conversion to secondary progressive MS (SPMS), new data show. Antje Bischof, MD, with…
November 26, 2018 News by Ana Pena PhD FDA Warns of Rare Risk of Severe Worsening in MS Disability After Stopping Gilenya Use The U.S. Food and Drug Administration (FDA) has issued a safety alert, warningĀ that people with relapsingĀ multiple sclerosis (MS)Ā who stop usingĀ Gilenya (fingolimod) may experience disease worsening beyond that when starting the medicine or while taking it. Reported cases of such increases in MS disability upon stopping treatment are…